8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Mar 26, 2026·SEC
Incyte Corporation(INCY)Earnings, Financials & Key Ratios
INCY•NASDAQ
15.3× P/E·Price updated Jun 19, 2026
AboutIncyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.Show more
- Revenue$5.14B+21.2%
- EBITDA$1.44B+747.8%
- Net Income$1.29B+3845.0%
- EPS (Diluted)6.41+4173.3%
- Gross Margin91.47%+0.4%
- EBITDA Margin27.93%+599.4%
- Operating Margin26.12%+1282.2%
- Net Margin25.03%+3154.4%
- ROE29.87%+3855.2%
INCY Key Insights
Incyte Corporation (INCY) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 26.3% free cash flow margin
- ✓Strong 5Y sales CAGR of 14.0%
- ✓Share count reduced 4.7% through buybacks
- ✓Healthy 5Y average net margin of 16.8%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when INCY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
INCY Price & Volume
Incyte Corporation (INCY) stock price & volume — 10-year historical chart
Loading chart...
INCY Growth Metrics
Incyte Corporation (INCY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years21.17%
5 Years14.03%
3 Years14.84%
TTM21.48%
Profit CAGR
10 Years69.61%
5 Years-
3 Years55.73%
TTM6631.44%
EPS CAGR
10 Years70.99%
5 Years-
3 Years61.56%
TTM2112.5%
Return on Capital
10 Years9.16%
5 Years15.08%
3 Years14.5%
Last Year29.05%
INCY Recent Earnings
Incyte Corporation (INCY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
Apr 28, 2026Metric
Actual
Est
EPS
$1.81+31.2%
$1.38
Rev
$1.3B+4.7%
$1.2B
Q1 2026
Feb 10, 2026Metric
Actual
Est
EPS
$1.80-5.3%
$1.90
Rev
$1.5B+11.2%
$1.4B
Q4 2025
Oct 28, 2025Metric
Actual
Est
EPS
$2.26+36.1%
$1.66
Rev
$1.4B+0.9%
$1.4B
Q3 2025
Jul 29, 2025Metric
Actual
Est
EPS
$1.57+12.9%
$1.39
Rev
$1.2B-3.3%
$1.3B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $1.81vs $1.38+31.2% | $1.3Bvs $1.2B+4.7% |
| Q1 2026 | Feb 10, 2026 | $1.80vs $1.90-5.3% | $1.5Bvs $1.4B+11.2% |
| Q4 2025 | Oct 28, 2025 | $2.26vs $1.66+36.1% | $1.4Bvs $1.4B+0.9% |
| Q3 2025 | Jul 29, 2025 | $1.57vs $1.39+12.9% | $1.2Bvs $1.3B-3.3% |
Based on last 12 quarters of dataView full earnings history →
INCY Peer Comparison
Incyte Corporation (INCY) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ALKS | 7.5B | 44.99 | 31.46 | -5.25% | 9.78% | 8.82% | 0.04 | |
 JAZZ | 14.09B | 224.66 | -38.47 | 4.88% | 0.66% | 0.71% | 1.26 | |
 EXEL | 13.19B | 51.91 | 18.67 | 6.98% | 35.08% | 40.21% | 0.08 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% |
Compare INCY vs Peers
Incyte Corporation (INCY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INCY Income Statement
Incyte Corporation (INCY) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.54B | 1.88B | 2.16B | 2.67B | 2.99B | 3.39B | 3.7B | 4.24B | 5.14B | 5.36B |
Revenue Growth % | 38.93% | 22.5% | 14.71% | 23.53% | 11.98% | 13.67% | 8.87% | 14.76% | 21.22% | 21.48% |
Cost of Goods Sold | 110.16M | 127.59M | 147.28M | 161.63M | 187.34M | 253.35M | 315.15M | 377.72M | 438.72M | 436.56M |
COGS % of Revenue | 7.17% | 6.78% | 6.82% | 6.06% | 6.27% | 7.46% | 8.53% | 8.91% | 8.53% | - |
Gross Profit | 1.43B▲ 0% | 1.75B▲ 23.0% | 2.01B▲ 14.7% | 2.51B▲ 24.5% | 2.8B▲ 11.7% | 3.14B▲ 12.2% | 3.38B▲ 7.6% | 3.86B▲ 14.3% | 4.7B▲ 21.7% | 4.92B▲ 0% |
Gross Margin % | 92.83% | 93.22% | 93.18% | 93.94% | 93.73% | 92.54% | 91.47% | 91.09% | 91.47% | 91.86% |
Gross Profit Growth % | 42.36% | 23.02% | 14.66% | 24.54% | 11.73% | 12.23% | 7.62% | 14.29% | 21.72% | - |
Operating Expenses | 1.66B | 1.6B | 1.59B | 2.75B | 2.16B | 2.54B | 2.73B | 3.78B | 3.36B | 3.49B |
OpEx % of Revenue | 108.17% | 84.96% | 73.64% | 102.95% | 72.38% | 74.87% | 73.84% | 89.2% | 65.35% | - |
Selling, General & Admin | 335.61M | 400.94M | 435.68M | 516.9M | 703.22M | 955.78M | 1.1B | 1.18B | 1.38B | 1.38B |
SG&A % of Revenue | 21.85% | 21.31% | 20.18% | 19.38% | 23.55% | 28.16% | 29.8% | 27.74% | 26.77% | - |
Research & Development | 1.33B | 1.2B | 1.15B | 2.22B | 1.46B | 1.59B | 1.63B | 2.61B | 1.98B | 2.1B |
R&D % of Revenue | 86.32% | 63.66% | 53.46% | 83.1% | 48.83% | 46.72% | 44.04% | 61.46% | 38.58% | - |
Other Operating Expenses | 0 | 0 | 0 | 12.52M | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -235.68M▲ 0% | 155.4M▲ 165.9% | 421.69M▲ 171.4% | -240.29M▼ 157.0% | 637.54M▲ 365.3% | 599.56M▼ 6.0% | 651.77M▲ 8.7% | 80.14M▼ 87.7% | 1.34B▲ 1575.4% | 1.44B▲ 0% |
Operating Margin % | -15.34% | 8.26% | 19.53% | -9.01% | 21.35% | 17.66% | 17.64% | 1.89% | 26.12% | 26.85% |
Operating Income Growth % | -243.69% | 165.93% | 171.36% | -156.98% | 365.32% | -5.96% | 8.71% | -87.7% | 1575.43% | - |
EBITDA | -183.5M | 210.37M | 476.22M | -188.48M | 695.38M | 667.42M | 734.43M | 169.39M | 1.44B | 1.53B |
EBITDA Margin % | -11.95% | 11.18% | 22.06% | -7.07% | 23.29% | 19.66% | 19.87% | 3.99% | 27.93% | 28.62% |
EBITDA Growth % | -182.49% | 214.64% | 126.38% | -139.58% | 468.93% | -4.02% | 10.04% | -76.94% | 747.76% | 418.04% |
D&A (Non-Cash Add-back) | 52.18M | 54.97M | 54.53M | 51.81M | 57.84M | 67.86M | 82.66M | 89.25M | 93.29M | 94.73M |
EBIT | -305.39M | 116.89M | 488.65M | -230.04M | 572.35M | 531.78M | 836.77M | 318.91M | 1.67B | 1.78B |
Net Interest Income | -6.9M | -1.54M | -1.85M | -2.17M | -1.91M | -2.67M | -2.55M | 126.43M | 103.17M | 114.02M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 128.71M | 105.6M | 116.36M |
Interest Expense | 6.9M | 1.54M | 1.85M | 2.17M | 1.91M | 2.67M | 2.55M | 2.28M | 2.43M | 2.34M |
Other Income/Expense | -76.61M | -40.05M | 65.1M | 8.07M | -67.09M | -70.45M | 182.44M | 236.49M | 321.7M | 334.53M |
Pretax Income | -312.29M▲ 0% | 115.35M▲ 136.9% | 486.79M▲ 322.0% | -232.22M▼ 147.7% | 570.44M▲ 345.7% | 529.12M▼ 7.2% | 834.22M▲ 57.7% | 316.63M▼ 62.0% | 1.66B▲ 425.7% | 1.77B▲ 0% |
Pretax Margin % | -20.33% | 6.13% | 22.55% | -8.71% | 19.1% | 15.59% | 22.57% | 7.47% | 32.37% | 33.09% |
Income Tax | 852K | 5.85M | 39.88M | 63.48M | -378.14M | 188.46M | 236.62M | 284.01M | 377.8M | 342.08M |
Effective Tax Rate % | -0.27% | 5.08% | 8.19% | -27.34% | -66.29% | 35.62% | 28.36% | 89.7% | 22.7% | 19.28% |
Net Income | -313.14M▲ 0% | 109.49M▲ 135.0% | 446.91M▲ 308.2% | -295.7M▼ 166.2% | 948.58M▲ 420.8% | 340.66M▼ 64.1% | 597.6M▲ 75.4% | 32.62M▼ 94.5% | 1.29B▲ 3845.0% | 1.43B▲ 0% |
Net Margin % | -20.38% | 5.82% | 20.7% | -11.09% | 31.76% | 10.04% | 16.17% | 0.77% | 25.03% | 26.71% |
Net Income Growth % | -400.46% | 134.97% | 308.16% | -166.17% | 420.79% | -64.09% | 75.42% | -94.54% | 3844.96% | 6631.44% |
Net Income (Continuing) | -313.14M | 109.49M | 446.91M | -295.7M | 948.58M | 340.66M | 597.6M | 32.62M | 1.29B | 1.43B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.53▲ 0% | 0.51▲ 133.3% | 2.05▲ 302.0% | -1.36▼ 166.3% | 4.27▲ 414.0% | 1.52▼ 64.4% | 2.65▲ 74.3% | 0.15▼ 94.3% | 6.41▲ 4173.3% | 6.92▲ 0% |
EPS Growth % | -383.33% | 133.33% | 301.96% | -166.34% | 413.97% | -64.4% | 74.34% | -94.34% | 4173.33% | 2112.5% |
EPS (Basic) | -1.53 | 0.52 | 2.08 | -1.36 | 4.30 | 1.53 | 2.67 | 0.16 | 6.59 | - |
Diluted Shares Outstanding | 204.58M | 215.63M | 217.66M | 218.07M | 222.07M | 223.96M | 225.93M | 210.53M | 200.7M | 206.83M |
Basic Shares Outstanding | 204.58M | 212.38M | 214.91M | 218.07M | 220.43M | 222M | 223.63M | 207.11M | 195.2M | 199.34M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
INCY Balance Sheet
Incyte Corporation (INCY) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.5B | 1.83B | 2.48B | 2.36B | 3.12B | 4.09B | 4.65B | 3.24B | 5.02B | 5.48B |
Cash & Short-Term Investments | 1.17B | 1.44B | 2.12B | 1.8B | 2.35B | 3.24B | 3.66B | 2.16B | 3.58B | 4.02B |
Cash Only | 899.51M | 1.16B | 1.83B | 1.51B | 2.06B | 2.95B | 3.21B | 1.69B | 3.1B | 3.46B |
Short-Term Investments | 270.14M | 274.34M | 284.87M | 288.37M | 290.75M | 287.54M | 442.67M | 470.26M | 482.79M | 554.71M |
Accounts Receivable | 266.3M | 307.6M | 308.81M | 481.99M | 616.3M | 644.88M | 743.56M | 853.15M | 1.02B | 1.05B |
Days Sales Outstanding | 63.27 | 59.66 | 52.21 | 65.97 | 75.33 | 69.34 | 73.44 | 73.42 | 72.73 | 64.93 |
Inventory | 6.48M | 6.97M | 11.4M | 16.43M | 27.9M | 41.99M | 62.97M | 58.87M | 101.06M | 115.62M |
Days Inventory Outstanding | 21.48 | 19.93 | 28.25 | 37.09 | 54.37 | 60.5 | 72.93 | 56.89 | 84.08 | 80.17 |
Other Current Assets | 62.43M | 79.37M | 43.73M | 60.1M | 126.28M | 167.01M | 182.83M | 168.91M | 317.83M | 0 |
Total Non-Current Assets | 797.73M | 813.51M | 945.26M | 1.2B | 1.81B | 1.75B | 2.14B | 2.21B | 1.52B | 1.82B |
Property, Plant & Equipment | 259.76M | 319.75M | 406.63M | 588.08M | 751.47M | 765.61M | 777.05M | 794.21M | 758.4M | 746.84M |
Fixed Asset Turnover | 5.91x | 5.89x | 5.31x | 4.53x | 3.97x | 4.43x | 4.76x | 5.34x | 6.78x | 6.79x |
Goodwill | 155.59M | 155.59M | 155.59M | 155.59M | 155.59M | 155.59M | 155.59M | 155.59M | 133M | 133M |
Intangible Assets | 236.9M | 215.36M | 193.83M | 172.29M | 150.75M | 129.22M | 123.55M | 113.8M | 117.13M | 110.16M |
Long-Term Investments | 134.36M | 99.2M | 133.66M | 222.3M | 221.27M | 133.68M | 187.72M | 18.81M | 47.99M | 137.76M |
Other Non-Current Assets | 11.12M | 23.6M | 55.56M | 60.71M | 68.06M | 106.1M | 260.92M | 360.8M | -47.99M | 317.97M |
Total Assets | 2.3B▲ 0% | 2.65B▲ 14.9% | 3.43B▲ 29.5% | 3.56B▲ 3.9% | 4.93B▲ 38.5% | 5.84B▲ 18.4% | 6.78B▲ 16.1% | 5.44B▼ 19.7% | 6.96B▲ 27.8% | 7.34B▲ 0% |
Asset Turnover | 0.67x | 0.71x | 0.63x | 0.75x | 0.61x | 0.58x | 0.54x | 0.78x | 0.74x | 0.81x |
Asset Growth % | 40.52% | 14.9% | 29.52% | 3.92% | 38.54% | 18.4% | 16.11% | -19.73% | 27.8% | 106.62% |
Total Current Liabilities | 375.4M | 425.28M | 513.34M | 631.2M | 854.31M | 1.16B | 1.24B | 1.64B | 1.52B | 1.49B |
Accounts Payable | 67.67M | 103.83M | 83.65M | 98.77M | 172.11M | 277.55M | 109.6M | 197.47M | 209.94M | 228.62M |
Days Payables Outstanding | 224.22 | 297.02 | 207.3 | 223.03 | 335.34 | 399.86 | 126.94 | 190.82 | 174.66 | 178 |
Short-Term Debt | 7.39M | 0 | 18.3M | 0 | 0 | 0 | 0 | 0 | 10.21M | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 158.88M | 171.36M | 226.72M | 260.06M | 328.26M | 435.86M | 545.01M | 724.83M | 1.07B | 39.38M |
Current Ratio | 4.01x | 4.31x | 4.83x | 3.74x | 3.65x | 3.54x | 3.75x | 1.97x | 3.32x | 3.68x |
Quick Ratio | 3.99x | 4.29x | 4.81x | 3.71x | 3.62x | 3.50x | 3.69x | 1.94x | 3.25x | 3.60x |
Cash Conversion Cycle | -139.48 | -217.43 | -126.83 | -119.97 | -205.64 | -270.02 | 19.43 | -60.5 | -17.86 | -32.9 |
Total Non-Current Liabilities | 296.56M | 294.52M | 315M | 318.45M | 309.04M | 313.79M | 351.89M | 354.85M | 288.2M | 226.6M |
Long-Term Debt | 16.61M | 17.43M | 0 | 0 | 0 | 0 | 0 | 0 | 14.51M | 0 |
Capital Lease Obligations | 0 | 0 | 31.92M | 32.57M | 31.63M | 30.08M | 29.16M | 33.54M | 44.71M | 136.76M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.88M | 12.88M |
Other Non-Current Liabilities | 279.95M | 277.08M | 283.09M | 285.88M | 277.41M | 283.7M | 322.73M | 321.31M | 216.11M | 197.19M |
Total Liabilities | 671.95M | 719.79M | 828.34M | 949.65M | 1.16B | 1.47B | 1.59B | 2B | 1.8B | 1.79B |
Total Debt | 24M | 36.13M | 60.23M | 47.53M | 44.82M | 41.46M | 38.29M | 43.54M | 69.43M | 33.83M |
Net Debt | -875.51M | -1.13B | -1.77B | -1.47B | -2.01B | -2.91B | -3.18B | -1.64B | -3.03B | -3.43B |
Debt / Equity | 0.01x | 0.02x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x |
Debt / EBITDA | - | 0.17x | 0.13x | - | 0.06x | 0.06x | 0.05x | 0.26x | 0.05x | 0.02x |
Net Debt / EBITDA | - | -5.36x | -3.72x | - | -2.89x | -4.36x | -4.32x | -9.71x | -2.11x | -2.23x |
Interest Coverage | -44.26x | 75.76x | 263.42x | -105.82x | 299.97x | 199.47x | 328.01x | 139.87x | 686.52x | 759.79x |
Total Equity | 1.63B▲ 0% | 1.93B▲ 18.1% | 2.6B▲ 34.9% | 2.61B▲ 0.5% | 3.77B▲ 44.4% | 4.37B▲ 15.9% | 5.19B▲ 18.8% | 3.45B▼ 33.6% | 5.17B▲ 49.9% | 5.55B▲ 0% |
Equity Growth % | 288.74% | 18.11% | 34.91% | 0.5% | 44.37% | 15.92% | 18.76% | -33.57% | 49.89% | 187.11% |
Book Value per Share | 7.97 | 8.93 | 11.94 | 11.97 | 16.98 | 19.51 | 22.97 | 16.38 | 25.75 | 26.84 |
Total Shareholders' Equity | 1.63B | 1.93B | 2.6B | 2.61B | 3.77B | 4.37B | 5.19B | 3.45B | 5.17B | 5.55B |
Common Stock | 211K | 213K | 216K | 219K | 221K | 223K | 224K | 193K | 198K | 200K |
Retained Earnings | -1.99B | -1.88B | -1.43B | -1.73B | -777.87M | -437.21M | 160.38M | -1.07B | 213.77M | 517.1M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -7.01M | -10.16M | -15.54M | -15.36M | -19.45M | 15.07M | 13.11M | -13.12M | 25.46M | 22.31M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INCY Cash Flow Statement
Incyte Corporation (INCY) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -92.99M | 336.23M | 710.66M | -124.6M | 749.49M | 969.94M | 496.49M | 335.34M | 1.41B | 1.52B |
Operating CF Margin % | -6.05% | 17.87% | 32.92% | -4.67% | 25.1% | 28.57% | 13.43% | 7.91% | 27.49% | - |
Operating CF Growth % | -130.51% | 461.58% | 111.36% | -117.53% | 701.52% | 29.41% | -48.81% | -32.46% | 321.52% | 269.05% |
Net Income | -313.14M | 109.49M | 446.91M | -295.7M | 948.58M | 340.66M | 597.6M | 32.62M | 1.29B | 1.43B |
Depreciation & Amortization | 52.18M | 54.97M | 54.53M | 51.81M | 57.84M | 67.86M | 82.66M | 89.25M | 93.29M | 94.73M |
Stock-Based Compensation | 133.06M | 148.15M | 166.59M | 177.88M | 183.01M | 188.42M | 215.89M | 266.06M | 249.35M | 190.33M |
Deferred Taxes | 91.16M | -459K | -377K | -350K | -465.6M | 57.09M | -158.9M | -85.55M | 247.69M | 317.81M |
Other Non-Cash Items | 7.99M | 70.61M | -14.29M | 13.51M | 40.23M | 117.11M | 7.89M | -105.28M | 63.69M | 102.74M |
Working Capital Changes | -64.23M | -46.54M | 57.3M | -71.74M | -14.57M | 198.81M | -248.65M | 138.24M | -527.16M | -620.6M |
Change in Receivables | -117.54M | -41.3M | -1.21M | -173.19M | -134.31M | -28.58M | -98.68M | -111.59M | -170.77M | -228.75M |
Change in Inventory | 4.85M | 4.04M | -6.1M | -19.47M | -20.96M | -67.5M | -170.15M | -127.63M | -58.51M | -42.16M |
Change in Payables | -7.93M | 36.16M | -20.18M | 15.12M | 73.34M | 105.44M | -167.94M | 88.16M | 6.56M | 32.17M |
Cash from Investing | -349.98M | -86.42M | -87.45M | -269M | -207.7M | -78.54M | -207.68M | 157.52M | -102.61M | -191.91M |
Capital Expenditures | -111.02M | -73.48M | -78.06M | -187.38M | -181.01M | -77.83M | -47.49M | -86.26M | -58.87M | -65.9M |
CapEx % of Revenue | 7.23% | 3.9% | 3.62% | 7.03% | 6.06% | 2.29% | 1.28% | 2.03% | 1.15% | 1.23% |
Acquisitions | 111.02M | 73.48M | 78.06M | 187.38M | 181.01M | 709K | 47.49M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -111.02M | -73.48M | -78.06M | -187.38M | -181.01M | -709K | -47.49M | -13.9M | -25M | -30M |
Cash from Financing | 690.17M | 14.66M | 45.71M | 71.71M | 6.18M | -794K | -20.03M | -2.02B | 101.04M | 198.54M |
Debt Issued (Net) | 0 | 0 | -822K | -836K | -2.42M | -2.86M | -3.36M | -3.8M | -4.54M | -4.64M |
Equity Issued (Net) | 649.39M | 29.94M | 63.3M | 110.31M | 58.63M | 61.12M | 35.84M | -2B | 202.66M | 290.46M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2B | -19.1M | -25.98M |
Other Financing | 49.72M | -15.29M | -16.77M | -37.76M | -50.03M | -59.05M | -52.51M | -12.96M | -97.08M | -87.29M |
Net Change in Cash | 247.17M▲ 0% | 264.55M▲ 7.0% | 668.72M▲ 152.8% | -318.94M▼ 147.7% | 544.39M▲ 270.7% | 893.96M▲ 64.2% | 262.1M▼ 70.7% | -1.53B▼ 682.1% | 1.41B▲ 192.4% | 1.52B▲ 0% |
Free Cash Flow | -204.01M▲ 0% | 262.74M▲ 228.8% | 632.59M▲ 140.8% | -311.98M▼ 149.3% | 568.48M▲ 282.2% | 892.11M▲ 56.9% | 449M▼ 49.7% | 249.07M▼ 44.5% | 1.35B▲ 443.9% | 1.45B▲ 0% |
FCF Margin % | -13.28% | 13.96% | 29.3% | -11.7% | 19.04% | 26.28% | 12.15% | 5.87% | 26.35% | 27.06% |
FCF Growth % | -210.59% | 228.79% | 140.76% | -149.32% | 282.22% | 56.93% | -49.67% | -44.53% | 443.87% | 402.37% |
FCF per Share | -1.00 | 1.22 | 2.91 | -1.43 | 2.56 | 3.98 | 1.99 | 1.18 | 6.75 | 7.01 |
FCF Conversion (FCF/Net Income) | 0.30x | 3.07x | 1.59x | 0.42x | 0.79x | 2.85x | 0.83x | 10.28x | 1.10x | 1.01x |
Interest Paid | 314K | 268K | 239K | 0 | 396K | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 6.3M | 5.42M | 33.55M | 70.71M | 67.73M | 136.24M | 378.21M | 373.06M | 0 | 175.59M |
INCY Key Ratios
Incyte Corporation (INCY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -30.55% | 6.16% | 19.76% | -11.35% | 29.73% | 8.37% | 12.5% | 0.76% | 29.87% | 29.31% |
Return on Invested Capital (ROIC) | -30.12% | 15.01% | 38.95% | -18.28% | 32.94% | 27.95% | 28.13% | 3.15% | 51.09% | 49.29% |
Gross Margin | 92.83% | 93.22% | 93.18% | 93.94% | 93.73% | 92.54% | 91.47% | 91.09% | 91.47% | 91.86% |
Net Margin | -20.38% | 5.82% | 20.7% | -11.09% | 31.76% | 10.04% | 16.17% | 0.77% | 25.03% | 26.71% |
Debt / Equity | 0.01x | 0.02x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x |
Interest Coverage | -44.26x | 75.76x | 263.42x | -105.82x | 299.97x | 199.47x | 328.01x | 139.87x | 686.52x | 759.79x |
FCF Conversion | 0.30x | 3.07x | 1.59x | 0.42x | 0.79x | 2.85x | 0.83x | 10.28x | 1.10x | 1.01x |
Revenue Growth | 38.93% | 22.5% | 14.71% | 23.53% | 11.98% | 13.67% | 8.87% | 14.76% | 21.22% | 21.48% |
Related:INCY Dividend History·INCY Revenue History·INCY Price History·INCY P/E History·INCY Financial Ratios·INCY Institutional Holders
INCY SEC Filings & Documents
Incyte Corporation (INCY) SEC filings — annual & quarterly reports (10-K, 10-Q)
INCY Frequently Asked Questions
Incyte Corporation (INCY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Incyte Corporation (INCY) reported $5.36B in revenue for fiscal year 2025. This represents a 12725% increase from $41.8M in 1996.
Incyte Corporation (INCY) grew revenue by 21.2% over the past year. This is strong growth.
Yes, Incyte Corporation (INCY) is profitable, generating $1.43B in net income for fiscal year 2025 (25.0% net margin).
Dividend & Returns
Incyte Corporation (INCY) has a return on equity (ROE) of 29.9%. This is excellent, indicating efficient use of shareholder capital.
Incyte Corporation (INCY) generated $1.45B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.